(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average b	urden					
hours per response	0.5					

longer subject to Section 16. Form 4 or Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Grossbard Elliott B					2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]						5. R	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) (First) (Middle) RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.					3. Date of Earliest Transaction (Month/Day/Year) 01/31/2008						X	X Officer (give title below) Other (specify below) EVP, CMO					
(Street)				4. If .	4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
SOUTH	SAN FRA	NCISCO, CA 94	4080									orm med by wio	re man one rep	Jording 1 crson			
(Ci	ty)	(State)	(Zip)		Table I - Non-Derivative Securities Acqui							ired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Y	ear) Ex	2A. Deemed Execution Date, if any (Month/Day/Year)		(Instr. 8)		(A)	Securities Acqui or Disposed of str. 3, 4 and 5)	(D) Owned Following Transaction(s)			O F	wnership orm:	V. Nature of Indirect Beneficial	
				(IV				Code	V An	(A) or nount (D)	Price	Instr. 3 and 4)		(I	Indirect (Ownership (Instr. 4)	
Reminder:	Report on a s	separate line for each	n class of securities b	oeneficia	ally c	owned direc	tly o	Pe thi	rsons is form	who respond are not requi valid OMB co	red to resp	ond unles			sec 1	474 (9-02)	
			Table							d of, or Benefic ertible securiti		d					
	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code		5. Number Derivative Securities Acquired (or Dispose (D) (Instr. 3, 4 and 5)	(A) ed of	of 6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	e Derivative Securities Beneficially Owned Following Reported Transaction(Ownersh Form of Derivativ Security: Direct (I or Indire	Ownership (Instr. 4)		
				Code	V	(A)	(D)	Date Exercisa	ıble	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)		
Stock Option (Right to Buy)	\$ 26.45	01/31/2008		A		130,000		02/01/2	2008 <mark>(1</mark>	01/31/2018	Common Stock	130,000	\$ 0	130,000	D		

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Grossbard Elliott B RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080			EVP, CMO				

Signatures

/s/Dolly Vance (Attorney-in-Fact)	02/01/2008
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C.
- (1) The shares vest monthly over one (1) year from 1/01/08.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.